Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors

NEW YORK, January 6, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

STXS Research Report: ( http://get.analystsreview.com/pdf/?c=Stereotaxis&d=06-Jan-2015&s=STXS ),

KITE Research Report: ( http://get.analystsreview.com/pdf/?c=Kite%20Pharma&d=06-Jan-2015&s=KITE ),

ISIS Research Report: ( http://get.analystsreview.com/pdf/?c=ISIS%20Pharma&d=06-Jan-2015&s=ISIS ),

MRK Research Report: ( http://get.analystsreview.com/pdf/?c=Merck&d=06-Jan-2015&s=MRK ),

GM Research Report: ( http://get.analystsreview.com/pdf/?c=General%20Motors&d=06-Jan-2015&s=GM ).

============

--

Analyst Update: FDA Approval,Collaboration, and Monthly Sales

Reviewed by: Rohit Tuli, CFA®  

The US markets rattled on Monday and ended the day in red amid an indiscriminate sell-off triggered by a renewed plunge in crude oil prices which plummeted below $50 a barrel. The Dow Jones Industrial Average crushed 1.86%, to finish the day at 17,501.65. NASDAQ Composite edged 1.57% lower to 4,652.57 while S&P 500 suffered its largest one-day decline in three months, closing at 2,020.58, down 1.83%. The European markets also ended on a negative note as concerns over a potential Greek exit of the Eurozone continued to weigh on sentiment. Weakness in the Euro further dented investor confidence as the currency dropped to a 9-year low against the dollar on expectations of fresh European Central Bank stimulus. The Chinese shares however maintained their bullish tone on hopes of fresh measures from the government to kickstart the economy. Overall, the Asian markets finished the day on a mixed note.

Shares of the U.S.-based medical appliances and equipment developer Stereotaxis, Inc. (Stereotaxis) jumped over 22% on Monday, January 5, after the Company received U.S. Food and Drug Administration's (FDA) approval for its Vdrive® with V-CAS™ Catheter Advancement System in the U.S. This marks the Company's 3^rd Vdrive system product to be cleared for market entry. Know more about the Stereotaxis' latest approval for a Vdrive system in our exclusive research report.

Kite Pharma, Inc. (Kite Pharma) announced strategic research collaboration with Amgen to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite Pharma's engineered autologous cell therapy (eACT™) platform and Amgen's extensive array of cancer targets. Find further details of Kite Pharma's collaboration with Amgen on cancer immunotherapies in our exclusive report.

ISIS Pharmaceuticals, Inc. (ISIS Pharma) has entered into a global collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract. The collaboration brings together ISIS Pharma's RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation. Get further insights into ISIS Pharma's new collaboration with Janssen in our exclusive research report.

The clinical trial of an Ebola vaccine developed by Merck & Co., Inc. (Merck) and NewLink Genetics Corp. (NewLink) resumed on Monday, January 5, nearly a month after it was stopped as a precautionary measure, Reuters reported. The University of Geneva hospital has said that the Swiss regulatory agency allowed the resumption of trial at a lower dose. Read more about the Merck-NewLink's Ebola vaccine and the latest relief for the two drugmakers in our research report.

General Motors Company (General Motors) seems to have ended 2014 on a strong note, with December sales rising to the highest level in seven years. General Motors sold 274,483 vehicles in December 2014, up 19% YoY. For viewing a comprehensive coverage of General Motors' December results, please visit our research report.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED